A population-based analysis of antidiabetic medications in four Canadian provinces: Secular trends and prescribing patterns.
Canada
/ epidemiology
Cohort Studies
Diabetes Mellitus, Type 2
/ drug therapy
Humans
Hypoglycemic Agents
/ administration & dosage
Insulin
/ administration & dosage
Metformin
/ administration & dosage
Pharmacovigilance
Practice Patterns, Physicians'
/ statistics & numerical data
Thiazolidinediones
/ administration & dosage
Canada
antidiabetic
antihyperglycemic
diabetes
drug utilization
pharmacoepidemiology
prescribing patterns
Journal
Pharmacoepidemiology and drug safety
ISSN: 1099-1557
Titre abrégé: Pharmacoepidemiol Drug Saf
Pays: England
ID NLM: 9208369
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
28
09
2018
revised:
14
05
2019
accepted:
09
07
2019
pubmed:
30
8
2019
medline:
17
12
2020
entrez:
30
8
2019
Statut:
ppublish
Résumé
To use the Canadian Network for Observational Drug Effect Studies (CNODES) to describe drug utilization of antidiabetic medications in four Canadian provinces. With the use of data from CNODES, we constructed cohorts of patients with type 2 diabetes in four Canadian provinces (Manitoba, Ontario, Quebec, and Saskatchewan) who received their first-ever prescription for a noninsulin antidiabetic medication during the study period, defined as the earliest date of data availability in each province (range: 1993-1998) to the latest date of the data extraction in each province (range: 2013-2014). Prescriptions rates were calculated for all prescriptions by class and described over time. Across provinces, we identified 650 830 patients who initiated antidiabetic medications during the study period. In most provinces, the overall prescription rate of antidiabetic medications increased during the last two decades. Metformin particularly increased in popularity, surpassing sulfonylureas in all provinces as the most widely prescribed antidiabetic medication by the early 2000s. Thiazolidinediones grew in popularity from the onset of their availability until 2006 to 2007, at which point they rapidly declined. Dipeptidyl peptidase-4 inhibitors saw substantial growth in several provinces following their addition to provincial formularies in 2008 to 2012, while glucagon-like peptide-1 agonists experienced modest growth. Insulin prescription rates remained constant or steadily increased over the last two decades. CNODES can be used for cross-jurisdictional drug utilization studies. In Canada, trends in antidiabetic medication prescriptions followed changing guidelines reflecting up-to-date knowledge of drug effectiveness and safety.
Substances chimiques
Hypoglycemic Agents
0
Insulin
0
Thiazolidinediones
0
Metformin
9100L32L2N
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
86-92Subventions
Organisme : CIHR
ID : DSE-146021
Pays : Canada
Informations de copyright
© 2019 John Wiley & Sons, Ltd.
Références
Lipscombe L, Booth G, Butalia S, et al. Pharmacologic glycemic management of type 2 diabetes in adults. Can J Diabetes. 2018;42:S88-S103.
American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2018. Diabetes Care. 2018;41:S73-S85.
Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2018 executive summary. Endocr Pract. 2018;24(1):91-120.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140-149.
Stein SA, Lamos EM, Davis SN. A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf. 2013;12(2):153-175.
Sardar P, Udell JA, Chatterjee S, Bansilal S, Mukherjee D, Farkouh ME. Effect of intensive versus standard blood glucose control in patients with type 2 diabetes mellitus in different regions of the world: systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2015;4:e001577.
Pelletier C, Dai S, Roberts K, Bienek A. Report summary diabetes in Canada: facts and figures from a public health perspective. Chronic Dis Inj Can. 2012;33(1):53-54.
Clemens KK, Liu K, Shariff S, Schernthaner G, Tangri N, Garg AX. Secular trends in antihyperglycaemic medication prescriptions in older adults with diabetes and chronic kidney disease: 2004-2013. Diabetes Obes Metab. 2016;18(6):607-614.
Clemens KK, Shariff S, Liu K, et al. Trends in antihyperglycemic medication prescriptions and hypoglycemia in older adults: 2002-2013. PLoS ONE. 2015;10(9):e0137596.
Alsabbagh MW, Mansell K, Lix LM, et al. Trends in prevalence, incidence and pharmacologic management of diabetes mellitus among seniors newly admitted to long-term care facilities in Saskatchewan between 2003 and 2011. Can J Diabetes. 2015;39(2):138-145.
Wang T-Y, Eguale T, Tamblyn R. Guidelines adherence in the treatment of patients with newly diagnosed type 2 diabetes: a historical cohort comparing the use of metformin in Quebec pre and post-Canadian Diabetes Association guidelines. BMC Health Serv Res. 2013;13:1.
Abdelmoneim AS, Eurich DT, Gamble J-M, Simpson SH. Use patterns of antidiabetic regimens by patients with type 2 diabetes. Can J Diabetes. 2013;37(6):394-400.
Morrow RL, Carney G, Wright JM, Bassett K, Sutherland J, Dormuth CR. Impact of rosiglitazone meta-analysis on use of glucose-lowering medications. Open Med. 2010;4:50-59.
Shah B, Juurlink D, Austin P, Mamdani M. New use of rosiglitazone decreased following publication of a meta-analysis suggesting harm. Diabet Med. 2008;25(7):871-874.
Morningstar B, Sketris IS, Kephart G, Sclar D. Trends in oral antihyperglycemic and insulin use in the Nova Scotia senior population (1993-1999). Can J Clin Pharmacol. 2001;9:123-129.
Foster P, Mamdani M, Juurlink D, Shah B, Paterson J, Gomes T. Trends in selection and timing of first-line pharmacotherapy in older patients with Type 2 diabetes diagnosed between 1994 and 2006. Diabet Med. 2013;30(10):1209-1213.
Neutel C, Campbell N, Morrison H. Trends in diabetes treatment in Canadians, 1994-2004. Chronic Dis Inj Can. 2010;30:107-111.
Rawson NS, Terres JAR. Rosiglitazone use and associated adverse event rates in Canada between 2004 and 2010. BMC Res Notes. 2013;6:1.
Suissa S, Henry D, Caetano P, et al. CNODES: the Canadian network for observational drug effect studies. Open Med. 2012;6:134-140.
Filion KB, Chateau D, Targownik LE, et al. Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis. Gut. 2013. gutjnl-2013-304738
Filion KB, Azoulay L, Platt RW, et al. A multicenter observational study of incretin-based drugs and heart failure. N Engl J Med. 2016;374(12):1145-1154.
Dormuth CR, Hemmelgarn BR, Paterson JM, et al. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. 2013;346:f880.
Drug Programs Policy and Strategy Branch. Ontario Drug Benefit Formulary/Comparative Drug Index: Ministry of Health and Long-Term Care; 2016.
Drug Plan & Extended Benefits Branch. Formulary: Saskatchewan Ministry of Health; 2012.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-1379.
Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.
Nathan DM, Buse JB, Davidson MB, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy a consensus statement from the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care. 2006;29(8):1963-1972.
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2003;27(suppl 2).
Khaw K-T, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ. 2001;322(7277):15-18.
Qaseem A, Vijan S, Snow V, Cross JT, Weiss KB, Owens DK. Glycemic control and type 2 diabetes mellitus: the optimal hemoglobin A1c targets. A guidance statement from the American College of Physicians. Ann Intern Med. 2007;147(6):417-422.
Seidu S, Achana F, Gray L, Davies M, Khunti K. Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials. Diabet Med. 2016;33(3):280-289.
UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
Vos RC, van Avendonk MJ, Jansen H, et al. Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control. Cochrane Database Syst Rev. 2016.
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes. 2008;32(suppl 1):S1-S201.
Initial management of blood glucose in adults with type 2 diabetes mellitus. McCulloch DK; 2016. (Accessed Nov 18, 2016, at https://www.uptodate.com/contents/initial-management-of-blood-glucose-in-adults-with-type-2-diabetes-mellitus.
Yki-Järvinen H. Thiazolidinediones. N Engl J Med. 2004;351:1106-1118.
Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab. 2001;86(1):280-288.
Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA. 2000;283(13):1695-1702.
Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279-1289.
Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation. 2002;106(6):679-684.
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356(24):2457-2471.
Hashim S, Gomes T, Juurlink D, Hellings C, Mamdani M. The rise and fall of the thiazolidinediones: impact of clinical evidence publication and formulary change on the prescription incidence of thiazolidinediones. J Popul Ther Clin Pharmacol. 2012;20:e238-e242.
Azoulay L, Yin H, Filion KB, et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ. 2012;344(may30 3):e3645.
Meltzer S, Leiter L, Daneman D, et al. 1998 clinical practice guidelines for the management of diabetes in Canada. Can Med Assoc J. 1998;159:S1-S29.
Harper W, Clement M, Goldenberg R, et al. Policies, guidelines and consensus statements: pharmacologic management of type 2 diabetes-2015 Interim Update. Can J Diabetes. 2015;39(4):250-252.
Harper W, Clement M, Goldenberg R, et al. Pharmacologic Management of Type 2 Diabetes. Can J Diabetes. 2013;37(Supplement 1):S61-S68.
Scheen AJ. The safety of gliptins: updated data in 2018. Expert Opin Drug Saf. 2018;17(4):387-405.
Secrest MH, Udell JA, Filion KB. The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors. Trends Cardiovasc Med. 2017;27(3):194-202.
Abdul-Ghani M, DeFronzo RA, Del Prato S, Chilton R, Singh R, Ryder RE. Cardiovascular disease and type 2 diabetes: has the dawn of a new era arrived? Diabetes Care. 2017;40(7):813-820.
d'Emden M, Amerena J, Deed G, Pollock C, Cooper ME. SGLT2 inhibitors with cardiovascular benefits: transforming clinical care in Type2 diabetes mellitus. Diabetes Res Clin Pract. 2017.
Cavender MA, Norhammar A, Birkeland KI, et al. SGLT-2 Inhibitors and Cardiovascular Risk: An Analysis of CVD-REAL. J Am Coll Cardiol. 2018;71(22):2497-2506.